	US 12,029,779 B2
	Semaglutide in medical therapy
Marianne Oelholm Larsen Groenning, Hareskov (DK); Lars Endahl, Lyngby (DK); Charlotte Giwercman Carson, Copenhagen (DK); Anders Bjerring Strathe, Farum (DK); Maria Kabisch, Koebenhavn S (DK); and Thomas Hansen, Broenshoej (DK)
Assigned to Novo Nordisk A/S, Bagsvaerd (DK)
Filed by Novo Nordisk A/S, Bagsvaerd (DK)
Filed on Apr. 9, 2020, as Appl. No. 16/844,552.
Application 16/844,552 is a continuation of application No. PCT/EP2018/077654, filed on Oct. 10, 2018.
Claims priority of application No. 17196254 (EP), filed on Oct. 12, 2017.
Prior Publication US 2020/0237876 A1, Jul. 30, 2020
Int. Cl. A61K 38/26 (2006.01); A61K 9/00 (2006.01); A61P 3/04 (2006.01)

CPC A61K 38/26 (2013.01) [A61P 3/04 (2018.01); A61K 9/0019 (2013.01)]

14 Claims

1. A method for reducing body weight of a subject in need thereof, comprising administering semaglutide subcutaneously to the subject in an amount of about 2.4 mg weekly.